Collins Helen's Insider Trades & SAST Disclosures
Collins Helen's most recent trade in Enliven Therapeutics Inc was a trade of 171,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Feb. 6, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Collins Helen.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Enliven Therapeutics Inc | Helen Collins | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 171,000 | 171,000 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Helen Collins | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 18 Oct 2024 | 816 | 816 | - | 2.5 | 2,024 | Common Stock |
| Enliven Therapeutics Inc | Helen Collins | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Oct 2024 | 816 | 266,268 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Helen Collins | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 18 Oct 2024 | 816 | 0 | - | 30.0 | 24,482 | Common Stock |
| IO Biotech Inc | Helen Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 45,642 | 45,642 | - | - | Stock Option (Right to Buy) | |
| Kura Oncology Inc | Helen Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 26,000 | 26,000 | - | - | Option to purchase common stock | |
| Enliven Therapeutics Inc | Helen Collins | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 11 Apr 2024 | 20,000 | 20,000 | - | 2.5 | 49,600 | Common Stock |
| Enliven Therapeutics Inc | Helen Collins | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Apr 2024 | 20,000 | 267,084 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Helen Collins | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 25.07 per share. | 11 Apr 2024 | 20,000 | 0 | - | 25.1 | 501,478 | Common Stock |
| Enliven Therapeutics Inc | Collins Helen | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 185,000 | 185,000 | - | - | Stock Option (right to buy) | |
| Kura Oncology Inc | Helen Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 26,000 | 26,000 | - | - | Option to purchase common stock | |
| Enliven Therapeutics Inc | Helen Collins | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2023 | 206,000 | 206,000 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Helen Collins | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 287,084 | 287,084 | - | - | Employee Stock Option (right to buy) | |
| Kura Oncology Inc | Helen Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 23,000 | 23,000 | - | - | Option to purchase common stock | |
| Kura Oncology Inc | Helen Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2021 | 46,000 | 46,000 | - | - | Option to purchase common stock | |
| Kura Oncology Inc | Helen Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2021 | 19,166 | 19,166 | - | - | Option to purchase common stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges